BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paolini M, Poul L, Berjaud C, Germain M, Darmon A, Bergère M, Pottier A, Levy L, Vibert E. Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel. Int J Nanomedicine 2017;12:5537-56. [PMID: 28814868 DOI: 10.2147/IJN.S141145] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Cui W, Zhao H, Wang C, Chen Y, Luo C, Zhang S, Sun B, He Z. Co-encapsulation of docetaxel and cyclosporin A into SNEDDS to promote oral cancer chemotherapy. Drug Deliv 2019;26:542-50. [PMID: 31090467 DOI: 10.1080/10717544.2019.1616237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
2 Imai H, Saijo K, Komine K, Otsuki Y, Ohuchi K, Sato Y, Okita A, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C. Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study. Cancer Manag Res 2019;11:7953-65. [PMID: 31686910 DOI: 10.2147/CMAR.S215697] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
3 Kim KT, Lee JY, Kim DD, Yoon IS, Cho HJ. Recent Progress in the Development of Poly(lactic-co-glycolic acid)-Based Nanostructures for Cancer Imaging and Therapy. Pharmaceutics 2019;11:E280. [PMID: 31197096 DOI: 10.3390/pharmaceutics11060280] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 14.5] [Reference Citation Analysis]
4 Kunduru KR, Jana T. Carbohydrate Therapeutics Based on Polymer-Grafted Glyconanoparticles: Synthetic Methods and Applications. Materials Horizons: From Nature to Nanomaterials 2019. [DOI: 10.1007/978-981-32-9804-0_6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Mandal S, Kang G, Prathipati PK, Fan W, Li Q, Destache CJ. Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study. Antiviral Res 2018;156:85-91. [PMID: 29885378 DOI: 10.1016/j.antiviral.2018.06.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
6 Yang Z, Duan J, Wang J, Liu Q, Shang R, Yang X, Lu P, Xia C, Wang L, Dou K. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy. Int J Nanomedicine 2018;13:1851-65. [PMID: 29618926 DOI: 10.2147/IJN.S155537] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
7 Germain M, Meyre ME, Poul L, Paolini M, Berjaud C, Mpambani F, Bergere M, Levy L, Pottier A. Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile. Sci Rep 2018;8:4797. [PMID: 29556068 DOI: 10.1038/s41598-018-23140-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
8 Jonsson-schmunk K, Schafer SC, Croyle MA. Impact of nanomedicine on hepatic cytochrome P450 3A4 activity: things to consider during pre-clinical and clinical studies. Journal of Pharmaceutical Investigation 2018;48:113-34. [DOI: 10.1007/s40005-017-0376-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]